Rman:
The ENMD move wasn't sympathy. Please see my posts to the thread.
Haven't got a position, and don't give a rat's butt if it gaps up or down on Monday, but....... at very least, the GERN crowd will have an alternative to think about. Extending from cancer, they will present Monday and Tuesday on plaque (restenosis) and adipose tissue (normalization of blood glucose), two big-market applications.
Regarding "bad for the sector".... after ENMD, we had to listen to Ron Insanna (CNBC) generalize about "biotechs" for the next six months. At first, even though it rallied in a vacuum (together with RGEN and a few other angio plays), we had to listen to his (and that of others, the wagging tongues and bobbing heads of biotech analysis and commentary at CNBC.... excluding Kernan, who always recognizes both the ridiculous and true promise) incessant talk about a biotech rally. Then, after it came back to earth and stayed there, we had to listen to months of his drivel about how the biotech business model stunk.
Sorry, but I believe that ENMD-like events hurt the sector. Today's stuff with GERN, however, was more reasonable. It's just a reflection of greedy, ignorant people, chasing a trade. It was hilarious.... we had hundreds of new biotech experts overnight.
Pre-1994, GERN is not unreasonably valued at this moment. Perspectives change.
Kudos on the opportunistic trading of late.
Rick |
